Ovarian cancer statistics, 2018

Lindsey A. Torre,Britton Trabert,Carol E. DeSantis,Kimberly D. Miller,Goli Samimi,Carolyn D. Runowicz,Mia M. Gaudet,Ahmedin Jemal,Rebecca L. Siegel

DOI: https://doi.org/10.3322/caac.21456

2018-05-29

Abstract:In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population-based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000) by 29% and the mortality rate declined between 1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. Ovarian cancer encompasses a heterogenous group of malignancies that vary in etiology, molecular biology, and numerous other characteristics. Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which incidence is highest in non-Hispanic whites (NHWs) (5.2 per 100,000) and lowest in non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) (3.4 per 100,000). Notably, however, APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages and help explain comparable epithelial cancer incidence for APIs and NHWs younger than 55 years. Most serous carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5-year cause-specific survival for patients diagnosed during 2007 through 2013 was 42% and 26%, respectively. For all stages of epithelial cancer combined, 5-year survival is highest in APIs (57%) and lowest in NHBs (35%), who have the lowest survival for almost every stage of diagnosis across cancer subtypes. Moreover, survival has plateaued in NHBs for decades despite increasing in NHWs, from 40% for cases diagnosed during 1992 through 1994 to 47% during 2007 through 2013. Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection. CA Cancer J Clin 2018;68:284-296. © 2018 American Cancer Society.

oncology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to provide a comprehensive overview of the occurrence of ovarian cancer in the United States, including incidence, mortality, survival rate and their trends, and summarize the current status of early detection strategies. Specifically, the paper focuses on the following aspects:

1. **Overall occurrence of ovarian cancer**: The paper provides the number of new ovarian cancer cases and the number of deaths in the United States in 2018, as well as the incidence and mortality rates among different racial/ethnic groups.

2. **Trends in incidence and mortality**: It analyzes the ovarian cancer incidence trends from 1985 to 2014 and the mortality trends from 1976 to 2015, and explores the reasons for these changes, such as changes in fertility patterns, the use of hormone replacement therapy, etc.

3. **Different subtypes of ovarian cancer**: It describes in detail the incidence, mortality and survival rates of different histological subtypes of ovarian cancer (such as serous carcinoma, endometrioid carcinoma, mucinous carcinoma and clear cell carcinoma), as well as the distribution characteristics of these subtypes in different age and racial/ethnic groups.

4. **Early detection strategies**: It reviews the current methods and strategies for early detection of ovarian cancer and emphasizes the importance of improving early detection, because early diagnosis can significantly improve the survival rate of patients.

5. **Racial/ethnic differences**: It explores the differences in ovarian cancer incidence and mortality among different racial/ethnic groups and analyzes the possible reasons for these differences, including the prevalence of risk factors, access to treatment, etc.

6. **Future research directions**: It proposes strategies to reduce the incidence and mortality of ovarian cancer, including reducing racial differences, further understanding the etiology and tumorigenesis mechanisms to promote the development of prevention and early detection methods.

Through these analyses, the paper aims to provide researchers, clinicians and policy - makers with the latest ovarian cancer epidemiological data and research progress in order to better meet the challenges posed by this disease.